Latest Depakote Stories

As more victims of Depakote use during pregnancy speak out about the birth defects that have affected the lives of their families, Depakote attorneys working with the Consumer Justice Foundation website http://www.depakotebirthinjury.com are trying to recoup compensation for the life long medical care that will be required to treat children born with skeletal defects. The Consumer Justice Foundation is a resource for the American people who have been adversely affected by corporate...

As lawsuits against the makers of the epilepsy drug Depakote begin to surface in the United States, Depakote lawyers begin to consult with families of birth defect victims about possible Depakote lawsuits. Depakote is a prescription anticonvulsant used to treat epilepsy and the manic phase of bipolar disorder. Depakote Birth Injury Resources provides online information about possible Depakote birth defects and means to connect with Depakote lawyers. (PRWEB) March 26, 2011 As new...

The prescription drug Depakote is currently the most prescribed branded treatment for patients with mania associated with bipolar disorder as well as for the treatment of epilepsy. Depakote is produced by Abbott Laboratories, a pharmaceutical company based in Abbott Park, North Chicago, Illinois. Currently, Abbot Laboratories is being evaluated by Depakote Birth Injury Resources ("DBIR" or DepakoteBirthInjury.com) for the high number of birth defects and birth injuries...

The US Food and Drug Administration has issued a warning to health care professionals and patients about the potential increased risk of birth injuries and birth defects when valproate sodium and related products (e.g. Depacon, Depakote or Stavzor) are used by mothers during pregnancy. Depakote Birth Injury Resources (DepakoteBirthInjury.com) offers information and resources about the possible side effects of valproate sodium, including neural tube malformations, craniofacial defects and...

ABBOTT PARK, Ill., Jan. 27 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2009. Diluted earnings per share, excluding specified items, were $1.18, reflecting 11.3 percent growth, at the high end of Abbott's previous forecast. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.98, up 10.1 percent.Worldwide sales increased 10.6 percent to nearly $8.8 billion, including a favorable 2.4...

ABBOTT PARK, Ill., Oct. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009. Diluted earnings per share, excluding specified items, were $0.92, above Abbott's guidance range of $0.88 to $0.90. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.95. The company is raising its ongoing earnings outlook for 2009 to $3.70 to $3.72, above its previous range of $3.65 to $3.70.Worldwide...

ABBOTT PARK, Ill., July 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2009.Diluted earnings per share, excluding specified items, were $0.89, at the high end of Abbott's second-quarter guidance range of $0.87 to $0.89. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.83. Worldwide operational sales, which excludes an unfavorable 8.0 percent effect of exchange rates, increased...

- Adjusted EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) - - Confirms Double-Digit EPS Guidance Range for 2009 - - Increased 2009 Dividend by 11 Percent - ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter...

BALTIMORE, July 31 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval for the Company's Abbreviated New Drug Application (ANDA) for Divalproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced. Lupin's Divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories' Depakote(R) tablets,...